Gossamer Bio (GOSS) Receivables (2024 - 2026)

Gossamer Bio has reported Receivables for 3 years, with the latest figure at $6.1 million in Q2 2026.

• On a quarterly basis, Receivables fell 23.49% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $6.1 million, a 23.49% decrease from a year earlier, with the FY2025 full-year figure at $12.5 million, up 126.2% from the prior year.
• Receivables was $6.1 million for Q2 2026 at Gossamer Bio, down from $9.4 million in the prior quarter.
• The five-year high for Receivables was $12.5 million in Q4 2025, with the low at $3.9 million in Q2 2024.
• Average Receivables over 3 years is $7.6 million, with a median of $6.7 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables jumped 126.2% in 2025, then decreased 23.49% in 2026.
• Over 3 years, Receivables stood at $5.5 million in 2024, then surged by 126.2% to $12.5 million in 2025, then slumped by 51.27% to $6.1 million in 2026.
• The last three Receivables figures came in at $6.1 million (Q2 2026), $9.4 million (Q1 2026), and $12.5 million (Q4 2025), per Business Quant data.